Uploaded October 2025 | Updated September 2026, 2 weeks ago
At the Milken Global Conference 2025, Dipal Doshi, CEO of Entrada Therapeutics, shared insights on patient-focused drug development and advancing therapies for rare diseases. With extensive experience in biotechnology, investment banking, and life sciences leadership, Dipal emphasizes partnerships with patient advocacy groups to ensure therapies are informed by real-world patient perspectives. He also serves on multiple biotech boards and is a Fellow of the Aspen Institute.
đź”— Stay Connected:
Buy a Copy of My New Book UNDUSRUPTED amzn.to/4g5gjH9
Visit my website: iankhan.com
Follow me on Twitter: twitter.com/IanKhanFuturist
Follow me on LinkedIn: linkedin.com/in/iankhanfuturist
Follow me on Facebook: facebook.com/iankhanfuturist
At the Milken Global Conference 2025, Dipal Doshi, CEO of Entrada Therapeutics, shared insights on patient-focused drug development and advancing therapies for rare diseases. With extensive experience in biotechnology, investment banking, and life sciences leadership, Dipal emphasizes partnerships with patient advocacy groups to ensure therapies are informed by real-world patient perspectives. He also serves on multiple biotech boards and is a Fellow of the Aspen Institute.
đź”— Stay Connected:
Buy a Copy of My New Book UNDUSRUPTED amzn.to/4g5gjH9
Visit my website: iankhan.com
Follow me on Twitter: twitter.com/IanKhanFuturist
Follow me on LinkedIn: linkedin.com/in/iankhanfuturist
Follow me on Facebook: facebook.com/iankhanfuturist
